ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2526

Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology

Rubén Queiro1, Ana Laiz2, Carlos Alberto Montilla-Morales3, Eva Galindez-Agirregoikoa4, Juan J. Bethencourt5 and Daniel Seoane6, 1Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, 2Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, 3Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 4Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, 5Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, 6Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Psoriatic arthritis, registries and spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

The natural history of psoriatic arthritis (PsA) is hardly known and the information regarding PsA prospective cohorts is very scarce worldwide. The information obtained from prospective cohorts of rheumatic diseases of recent onset is the only way to unravel the true natural history of these diseases. Our objective was to describe the baseline characteristics of the REAPSER (Recent-Onset PsA Registry of the Spanish Society of Rheumatology) cohort, a prospective cohort that seeks to know the natural history and the impact that the disease generates in Spanish patients with PsA.

Methods:

REAPSER is an observational, multicenter study, with consecutive recruitment, which includes adults of both sexes aged 18 yr or older that meet CASPAR criteria for PsA, and have less than two years of disease evolution (recent-onset PsA). Annual follow-up visits will be carried out for 5 years. Measurements include socio-demographic data, employment status, impact of disease, family history of PsA and other inflammatory diseases, comorbidities, lifestyle, use of health services, clinical status at disease presentation and during follow up, anthropometric data, clinical evaluation, radiographic progression, lab determinations, and treatment of the disease. The study has been approved by the ethical committees of the participating centers.

The statistical analysis is limited to describing percentages for qualitative variables and central measurements with dispersion values for the quantitative ones.

Results:

Two hundred and fifteen consecutive patients were included, mean age 49.8 ± 13.9 years.

Parameter

N: 215

Men

Women

Active worker

Unemployed

Retired / pensioner

Job change last year

University studies

Smoking

BMI

Weekly alcohol consumption (SDU)

Family history of psoriasis

Family history of PsA

Family history of other arthritis

Charlson’s Comorbidity Index

Psoriasis at baseline

PASI

Joint pattern

TJC68

SJC66

BASDAI

Dactylitis

Enthesitis

Uveitis

Pain VAS

Patient´s global disease activity

HAQ

PsAID

Steinbrocker Index (0-168)

Cardiovascular events

HLA-B27

ESR

NSAIDs

GC

Synthetic DMARDs

Biological DMARDS

67.4%

32.6%

59.5%

12.1%

17.7%

4.7%

20%

30.2%

27.7 ± 5.2

0 SDU (0-4)

41.4%

9.3%

6.5%

0: 46.5%. 1-2: 35.3%. 3-4: 14.4%. >4: 3.8%

88%

1.5 (0.6-4.3)

Peripheral: 81.5%. Axial: 5.2%. Mixed: 13.3%

4 (2-8)

2 (1-4)

3.9 (3-4.4)

41.9%

25%

0.5%

5 (3-7)

5 (3-7)

0.5 (0.1-4)

3.8 (1.8-6)

0 (0-4)

5.7%

12.3%

13 (6-25)

75%

28.3%

53.2%

1.5%

Values are expressed as percentages, means with standard deviation, and medians with IQR (interquartile range). SDU: Standard Drink Units. PsAID: Psoriatic Arthritis Impact of Disease.


Conclusion:

The baseline situation of Spanish patients with recent-onset PsA corresponds to that of a disease with slight cutaneous involvement and predominance of oligoarticular arthritis. Unsurprisingly, structural damage is scarce but not zero. The impact of the disease is still low in these early stages, however 18% of patients have a high Charlson´s comorbidity index (> 3) and almost 5% of patients changed their employment status in the last year due to their PsA.


Disclosure: R. Queiro, None; A. Laiz, None; C. A. Montilla-Morales, None; E. Galindez-Agirregoikoa, None; J. J. Bethencourt, None; D. Seoane, None.

To cite this abstract in AMA style:

Queiro R, Laiz A, Montilla-Morales CA, Galindez-Agirregoikoa E, Bethencourt JJ, Seoane D. Baseline Data from the Recent-Onset Psoriatic Arthritis Registry of the Spanish Society of Rheumatology [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/baseline-data-from-the-recent-onset-psoriatic-arthritis-registry-of-the-spanish-society-of-rheumatology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/baseline-data-from-the-recent-onset-psoriatic-arthritis-registry-of-the-spanish-society-of-rheumatology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology